Temporal patterns of lipolytic regulators in adipose tissue after acute growth hormone exposure in human subjects: A randomized controlled crossover trial

Mol Metab. 2019 Nov:29:65-75. doi: 10.1016/j.molmet.2019.08.013. Epub 2019 Aug 20.

Abstract

Objective: Growth hormone (GH) stimulates lipolysis, but the underlying mechanisms remain incompletely understood. We examined the effect of GH on the expression of lipolytic regulators in adipose tissue (AT).

Methods: In a randomized, placebo-controlled, cross-over study, nine men were examined after injection of 1) a GH bolus and 2) a GH-receptor antagonist (pegvisomant) followed by four AT biopsies. In a second study, eight men were examined in a 2 × 2 factorial design including GH infusion and 36-h fasting with AT biopsies obtained during a basal period and a hyperinsulinemic-euglycemic clamp. Expression of GH-signaling intermediates and lipolytic regulators were studied by PCR and western blotting. In addition, mechanistic experiments in mouse models and 3T3-L1 adipocytes were performed.

Results: The GH bolus increased circulating free fatty acids (p < 0.0001) together with phosphorylation of signal transducer and activator of transcription 5 (STAT5) (p < 0.0001) and mRNA expression of the STAT5-dependent genes cytokine-inducible SH2-containing protein (CISH) and IGF-1 in AT. This was accompanied by suppressed mRNA expression of G0/G1 switch gene 2 (G0S2) (p = 0.007) and fat specific protein 27 (FSP27) (p = 0.002) and upregulation of phosphatase and tensin homolog (PTEN) mRNA expression (p = 0.03). Suppression of G0S2 was also observed in humans after GH infusion and fasting, as well as in GH transgene mice, and in vitro studies suggested MEK-PPARγ signaling to be involved.

Conclusions: GH-induced lipolysis in human subjects in vivo is linked to downregulation of G0S2 and FSP27 and upregulation of PTEN in AT. Mechanistically, in vitro data suggest that GH acts via MEK to suppress PPARγ-dependent transcription of G0S2. ClinicalTrials.govNCT02782221 and NCT01209429.

Keywords: FSP27; G0S2; Growth hormone; Lipolysis; PTEN.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / metabolism*
  • Adipose Tissue / pathology
  • Adult
  • Animals
  • Apoptosis Regulatory Proteins / genetics
  • Apoptosis Regulatory Proteins / metabolism
  • Biomarkers / metabolism
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism
  • Cross-Over Studies
  • Down-Regulation / drug effects
  • Fatty Acids, Nonesterified / blood
  • Human Growth Hormone / administration & dosage*
  • Human Growth Hormone / analogs & derivatives*
  • Human Growth Hormone / pharmacology
  • Humans
  • Lipolysis
  • Male
  • Mice
  • Mice, Transgenic
  • PPAR gamma / metabolism
  • Placebo Effect
  • Signal Transduction
  • Young Adult

Substances

  • Apoptosis Regulatory Proteins
  • Biomarkers
  • CIDEC protein, human
  • Cell Cycle Proteins
  • Fatty Acids, Nonesterified
  • G0S2 protein, human
  • PPAR gamma
  • Human Growth Hormone
  • pegvisomant

Associated data

  • ClinicalTrials.gov/NCT02782221
  • ClinicalTrials.gov/NCT01209429